INTRODUCTION
Anticancer drugs despite showing progress in the treatment of malignant diseases are commonly associated with systematic toxicity and other effects 1, 2 . The common approach to overcome such difficulty and to increase the drug efficiency is to use the anticancer drug conjugated with other substitute. Hence, a molecule that shows suitable properties is chemically changed by coupling to another therapeutically active compound to achieve the best combination of properties in forming the most effective anticancer drug 3, 4 . Among these chemically modified drugs are the esters of fatty acids, chosen as anticancer drug conjugates because of their low toxicity 5, 6 .
It is reported that the fatty acids are taken up rapidly by tumor cells 7 and their hydrophobic nature facilitates their incorporation into the lipid bilayer of cells 8, 9 , resulting in disruption of membrane structure and fluidity 10 . In view of these characteristics of fatty acids, they have been widely used to enhance the anticancer activity of various chemo-therapeutic agents 11, 12 . It is also reported that fatty acids exhibit broad spectrum of activity which make them attractive molecules for preparing various biologically active compounds of interest in biomedical fields. In view of these properties, various fatty acids have been combined with therapeutically active compounds to produce novel hybrid molecules anticipating enhanced biological activity 13, 14 .
To attain effective tumor-specific drug delivery, the fatty acids have been chemically modified to improve their specificity, biological activity and lower toxicity against a range of therapeutic targets 15 . Studies on the synthesis of fatty acid esters, where fatty acid was conjugated with propofol in order to enhance its activity, lipid-solubility, bioavailability, and reduce its side-effects are reported 6, 15 19 .
Propofol diisopropylphenol is one of the most widely accepted chemical agents used for induction of anesthesia and is reported to be non-toxic to human at high concentrations 3-8 μg/mL; 20-50 μM 20 . The presence of two hydroxyl group in propofol exerts a steric hindrance that prevents entry of hydrophilic molecules to the hydroxyl group. This makes the molecule highly hydrophobic. While it is an intravenous sedative-hypnotic agent, propofol also shows preferential scavenging of organo-radical species. Clinically relevant concentrations of propofol are reported to decrease the metastatic potential of human cancer cells and have been shown to induce apoptosis involving both extrinsic and intrinsic pathways 21, 22 .
Earlier study on propofol-fatty acid conjugates was mostly concentrated on the long chain fatty acids including poly unsaturated fatty acids and there are no studies reported on the conjugates involving short chain and medium chain fatty acids 6, 17, 18 . In the present study, we selected four unusual fatty acids such as alpha-linolenic acid ALA , valproic acid VA , butyric acid BA and 2-ethylhexanoic acid 2-EHA which have not been employed for such conjugation with propofol. Each of these fatty acids have a wide range of applications and a brief description about each of these fatty acids has been provided. Alpha-linolenic acid ALA is an essential omega-3 fatty acid which should be obtained through diet. ALA is reported to possess a wide range of biological activities including nutraceutical applications and potential use in cardiovascular diseases 23 . ALA is also used to treat rheumatoid arthritis, multiple sclerosis, diabetes, lupus, ulcerative colitis, renal disease, and Crohn s disease 24, 25 .
Valproic acid VA , also known as dipropylacetic acid, is a branched eight carbon fatty acid that is reported as a potent anticancer agent inhibiting cancer cells both in vitro and in vivo 26 . VA s beneficial properties were serendipitously discovered while it was being used as a vehicle to deliver other compounds that were being tested for their anticonvulsant activity. Researchers also observed that it had substantial ability to prevent seizures 27 . Valproic acid derivatives are also found to be potent in anticonvulsant and antioxidant properties 28 30 .
Butyric acid BA is well known for its anticancer effects as it induces morphological and biochemical differentiation in a variety of cells leading to concomitant suppression of neoplastic properties 31 33 . Butyrates are also reported to help to protect colonic mucosa from oxidative stress and inhibit its inflammation while promoting satiety 34 . In view of this, several butyric acid derivatives have been designed and synthesized as prodrugs of butyric acid 35, 36 . BA esters such as methyl, ethyl, and amyl butyrates are also reported to be used as fragrant and flavoring agents in beverages, foods and cosmetic industries 37, 38 .
2-Ethylhexanoic acid 2-EHA , a branched aliphatic carboxylic acid is of particular importance in material science, catalysis, paint industries, lubricant industries and has a variety of commercial uses 39, 40 . It has been reported to have applications in cosmetics to produce emollients. In view of the above reported activities of the fatty acids we have employed them to couple with propofol as esters. Therefore, the present study was aimed at the synthesis, characterization and antiproliferative activity for the conjugates of propofol 2,4-diisopropylphenol 2,4 P and 2,6-diisopropylphenol 2,6 P esters of ALA, VA, BA and 2-EHA.
EXPERIMENTAL

Chemicals
The raw materials needed for the synthesis of propofolfatty acid ester conjugates of selected four fatty acids, such as alpha-linolenic acid ALA , was extracted from eripupal oil according to a reported procedure 41 
Analytical methods
IR spectra were recorded on a Perkin Elmer Model: Spectrum BX FT-IR spectrometer using CHCl 3 . All 1 H and 13 C spectra were recorded on 300 MHz Brucker and 500
MHz Varian spectrometers, respectively. HRMS data were recorded on a Thermo Scientific Exactive Orbitrap mass spectrometer Germany and are given in mass units m/z . ESI-MS spectra were recorded on Waters Model: Q STAR XL, Applied Biosystems, USA Mass Spectrometer equipped with an Electrospray Ionization source. Elemental analyses were carried out by using Elementar Vario Micro Cube instrument Germany . Gas chromatography was performed on an Agilent 6850 gas chromatograph equipped with a flame ionization detector. The column used was a HP-1 column having a length of 30 m, 0.25 mm i.d and 0.25 μm film thickness. The carrier gas was nitrogen at a flow rate of 1 mL min 1 . The oven programming was as follows: 150 for 2 minutes, which rose to 300 at a rate of 10 min 1 and held at 300 for 20 minutes. The injector and detector temperatures were maintained at 280 and 300 respectively.
Synthesis
Synthesis of propofol esters of ALA was carried out as shown in Fig. 1 . The synthesis involves esterification of propofol isomers i.e., 2,4-diisopropylphenol or 2,4-propofol and 2,6-diisopropylphenol or 2,6-propofol with ALA to get the desired compounds 2,4P-ALA and 2,6P-ALA. Other fatty acids such as VA, BA and 2-EHA were also esterified in the similar manner with propofol to obtain desired products like 2,4P-VA, 2,6P-VA, 2,4P-BA, 2,6P-BA, 2,4P-2-EHA and 2,6P-2-EHA. 2.3.1 General procedure for synthesis of propofol-fatty acid conjugates A synthetic approach was designed using the reported protocol 16 . A 1 equivalent amount of the individual fatty acid was dissolved in dichloromethane DCM . To this mixture, 1.05 equivalent of coupling reagent N,N-dicyclohexylcarbodiimide DCC was added and the reaction mixture was stirred for 15 min at room temperature followed by the addition of 1 equivalent of propofol isomer 2,6-propofol/2,4-propofol and 0.152 equivalents of 4-dimethylaminopyridine DMAP and the reaction mixture was stirred for a period of 12 h in the dark under nitrogen atmosphere. The progress of the reaction was monitored on thin layer chromatography TLC and the reaction products were detected in iodine vapour. Then the crude reaction product was filtered and the filtrate was concentrated under reduced pressure. Finally, the synthesized crude product was purified by silica gel column chromatography with solvent system hexane and ethyl acetate 98:2 v/v to obtain the corresponding esters. The purity of each ester was further monitored by GC. 
In vitro antiproliferative activity:
The cell lines, human epithelial lung carcinoma A-549 , breast adenocarcinoma MDA-MB-231 , human cervical HeLa , human pancreatic carcinoma Mia-Pa-Ca , human liver carcinoma HePG2 which were used in this study were procured from American Type Culture Collection ATCC , United States. The synthesized test compounds were evaluated for their in vitro antiproliferative activity in these five different human cancer cell lines followed by literature method 42 . A protocol of 48 hrs continuous drug exposure was used, and a SRB cell proliferation assay was used to estimate cell viability or growth. All the cell lines were grown in Dulbecco s modified Eagle s medium containing 10 FBS in a humidified atmosphere of 5 CO 2 at 37 . Cells were trypsinized when sub-confluent from T25 flasks/60 mm dishes and seeded in 96-well plates in 100 μL aliquots at plating densities depending on the doubling time of individual cell lines. The microtiter plates were incubated at 37 , 5 CO 2 , 95 air, and 100 relative humidity for 24 hrs prior to addition of experimental drugs and were incubated for 48 hrs with different doses 0.01, 0.1, 1, 10, 100 μM of prepared derivatives where DMSO treated cells were used as negative controls for propofol esters. After 48 hrs incubation at 37 , cell monolayers were fixed by the addition of 10 wt/vol cold trichloroacetic acid and incubated at 4 for 1hr and were then stained with 0.057 SRB dissolved in 1 acetic acid for 30 min at room temperature. Unbound SRB was washed with 1 acetic acid. The protein-bound dye was dissolved in 10 mM Tris base solution for OD determination at 510
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nm using a micro plate reader Enspire, Perkin Elmer, and USA . Using the seven absorbance measurements time zero, Tz , control growth, C , and test growth in the presence of drug at the five concentration levels Ti , the percentage growth was calculated at each of the drug concentrations levels. Percentage of growth inhibition was calculated as:
Ti-Tz / C-Tz 100 for concentrations for which Ti ≥ Tz Ti-Tz /Tz 100 for concentrations for which Ti Tz.
The dose response parameter, growth inhibition of 50 GI 50 was calculated from Ti-Tz / C-Tz 100 50, which is the drug concentration resulting in a 50 reduction in the net protein increase as measured by SRB staining in control cells during the drug incubation. Values were calculated for this parameter if the level of activity is reached. However, if the effect is not reached or is exceeded, the value for that parameter was expressed as greater or less than the maximum or minimum concentrations tested.
RESULTS AND DISCUSSION
Chemistry
In the present study, eight novel propofol-fatty acid conjugates were synthesized by a simple chemical method with mild reaction conditions and convenient product purification resulting in higher yields. The isolated yields in the present study were found to be in the range of 97.0-98.5 . All the products were purified by column chromatography and the pure products were characterized by IR, NMR, mass spectral and elemental analysis data. The structures of the products are shown in Fig. 2 . The IR spectra of the products showed a strong absorption at 1755 cm 1 characteristic of ester carbonyl functionality. The 1 H-NMR of 2,6-diisopropylphenol-butyric acid 2,6P-BA showed a triplet at δ 2.6 which is characteristic of protons adjacent to carbonyl and isopropyl group protons were observed at δ 1.19 whereas the aromatic protons in the diisopropylphenyl moiety were observed in the range of δ 7.25 to 7.11. Further the mass spectral data of the product showed the m/z at 249.18 M H which confirmed the structure of the compound.
Antiproliferative evaluation
The antiproliferative study of novel propofol-fatty acid conjugates was assessed on the five human cancer cell lines A-549, MDA-MB-231, HeLa, Mia-Pa-Ca and HePG2 using doxorubicin as a standard drug. The concentration of individual compounds at which 50 of the growth inhibition GI 50 was observed was calculated and results are given in the Table 1 .
From the anti-cancer activity data, it can be observed that all the conjugates exhibited good activity against the tested cell lines. Interestingly, each conjugate was showing very good activity against specific cell lines with some selectivity. All the conjugates showed excellent activity against A549, HeLa, Mia-Pa-Ca and HePG2 cell lines with a GI 50 value of 0.5 μM except on MDA-MB-231 cell line where the best GI 50 value observed was 1.0 μM. In general, the 2,4-isomers exhibited slightly higher activity compared to the 2,6-isomers when the total number of cell lines was taken into consideration. It can be observed that 2,4P-ALA and 2,4P-BA isomers were found to be more potent than the corresponding 2,6P-ALA and 2,6P-BA isomers. Based on the structure activity relationship studies in the present study, it was found that among all the esters tested, 2,6P-BA represented the highest activity against A549 cell line with a GI 50 value of 0.19 μM. The standard drug, doxorubicin had a GI 50 value of 0.07 μM against A549 cell line. On HeLa, the conjugates 2,6P-ALA and 2,4P-BA showed less activity while the remaining six conjugates showed moderate activity. It was found that 2,6P-VA exhibited highest activity against HeLa cell lines compared to other conjugates with a GI 50 value of 0.42 μM and doxorubicin represented a GI 50 value of 0.03 μM. On the Mia-Pa-Ca cell line, 2,6 P-VA showed highest activity with a GI 50 value of 0.47 μM whereas doxorubicin exhibited a GI 50 value of 0.08 μM. On HePG2 cell line, three esters showed promising activity. Among the three esters, it was found that, 2,4P-BA showed highest activity with a GI 50 value of 0.21 μM whereas 2,4P-2-EHA and 2,6 P-VA exhibited GI 50 values of 0.25 and 0.28 μM respectively. The standard drug, doxorubicin represented a GI 50 value of 0.06 against HePG2 cell line. It is interesting to observe that there was a clear difference in activity among isomers of 2,4-and 2,6-diisopropylphenyl esters derived from same fatty acid on the cell lines tested except on Mia-Pa-Ca where the difference in activity was less between two isomers. Earlier reports on the propofol-fatty acid conjugates also showed similar observations on cancer cell lines where the fatty acids used were normal long chain fatty acids 6, 19 .
Thus all propofol-fatty acid conjugates in this study exhibited promising antiproliferative activity on the cell lines tested.
CONCLUSIONS
In conclusion eight novel propofol-fatty acid conjugates have been synthesized and their antiproliferative activity was tested against five cancer cell lines in the present study. From the activity studies, it was found that all the synthesized propofol-fatty acid conjugates were able to inhibit the growth of cancer cells. Our preliminary data strongly suggest that the synthesized conjugates possess potent to moderate anticancer activity.
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